Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Prime Medicine, Inc.

PRME ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$3.90

▲ +11.43%

Market Cap $707.37M · Vol 2.24M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$707.37M

Small Cap

Div Yield

N/A

EPS Growth

+27.94%

YoY

RSI (14)

66.17

Momentum

Beta

2.40

vs Market

52W High

$6.85

48.91% below

52W Low

$2.68

30.84% above

Volume

2.24M

Avg 966.35K

P/B

5.18

Price-to-book

ROE

-146.81%

Return on equity

Free Float

79.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Prime Medicine, Inc. (PRME) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PRME pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+27.66%

+5.41%

-2.26%

+14.37%

YTD

+12.39%

-33.56%

-56.08%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$4.63M
Net Income	$-201,142,000.00
Revenue Growth (YoY)	+3.50%
Gross Margin	100.00%
Operating Margin	-4,498.06%
Net Profit Margin	-4,342.44%
ROE	-146.81%
ROA · ROIC	-62.83% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	111.44
P/B	5.18
P/FCF	N/A
EPS Growth	+27.94%
Outstanding Shares	181.38M

Technical Indicators

50-Day SMA	$3.25
200-Day SMA	$3.48
RSI (14)	66.17
Beta	2.40
52-Week High	$6.85
52-Week Low	$2.68

Volume Today	2.24M
Avg Daily Volume (30D)	966.35K
Relative Volume	2.32x
Volatility (10D)	85.70
Volatility (30D)	79.47
Free Float	79.69%

Analyst Consensus

BUY

Current Price $3.90

Mean Target $7.11

52W Low$2.68 52W High$6.85

Current

Target

$2.68 $6.85

Current Analyst target

+82.40% upside potential · 15 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG011RT3R64

ISINUS74168J1016

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.09% ARGX.BR argenx SE +0.46% ARGX argenx SE -0.22% 2269.HK WuXi Biologics (Cayman) Inc. -2.07% GMAB Genmab A/S -3.04%

Company Profile

Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its gene editing technology enables targeted modifications to genomic deoxyribonucleic acid (DNA) without introducing double-stranded breaks. The Company pipeline includes wholly owned in vivo programs targeting liver genetic diseases Wilson Disease, Alpha-1 Antitrypsin Deficiency (AATD) as well as early-stage discovery efforts in Cystic Fibrosis (CF). The PM359 is an ex vivo prime editing program designed to correct the GT mutation in the NCF1 gene, the most common cause of Chronic Granulomatous Disease (CGD). This program provides validation of prime editing in human cells. The Wilson Disease is a rare autosomal recessive disorder caused by loss-of-function mutations in ATP7B.